Literature DB >> 6133850

Alprazolam in older depressed inpatients.

W M Pitts, W E Fann, C Sajadi, S Snyder.   

Abstract

Alprazolam, a triazolobenzodiazepine first developed as an anxiolytic, has been shown to be effective in the treatment of depression in several comparison studies with tricyclic antidepressants. This open label study examined the efficacy and safety of alprazolam in patients aged 56-78. Of 18 patients with evaluable data, 12 were responders (improvement greater than or equal to 50% on the Hamilton Depression Rating Scale); 4 patients were partial responders (HAM-D improvement of 25%-49%); and 2 patients were nonresponders. Initial drowsiness was the only side effect observed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6133850

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  4 in total

1.  Pharmacological treatment of depression in the elderly.

Authors:  K H Clements
Journal:  Can Fam Physician       Date:  1990-05       Impact factor: 3.275

Review 2.  Alprazolam for depression.

Authors:  Harm van Marwijk; Gideon Allick; Froukje Wegman; Arjan Bax; Ingrid I Riphagen
Journal:  Cochrane Database Syst Rev       Date:  2012-07-11

Review 3.  Alprazolam: a review of its pharmacodynamic properties and efficacy in the treatment of anxiety and depression.

Authors:  G W Dawson; S G Jue; R N Brogden
Journal:  Drugs       Date:  1984-02       Impact factor: 9.546

Review 4.  Brief review of published alprazolam clinical studies.

Authors:  R N Straw
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.